Pre Diagnostics

Executive Summary

Pre Diagnostics is a Norwegian startup founded in 2022, dedicated to advancing precision medicine for Alzheimer's disease (AD) and related neurodegenerative conditions. The company's mission is to enable early detection, allowing treatment before irreversible damage occurs. By focusing on biomarkers and diagnostic tools, Pre Diagnostics aims to address a critical unmet need in neurodegeneration, where early intervention can dramatically alter disease progression. The company is privately held and operates at an early stage, with no disclosed funding or pipeline details to date. Its approach aligns with the growing trend toward blood-based biomarkers and point-of-care diagnostics, which promise to make screening more accessible and cost-effective. As the global burden of AD continues to rise, Pre Diagnostics has the potential to become a key player in the diagnostic ecosystem, provided it can secure funding and validate its technology through clinical studies. Given the company's early stage, the conviction score is moderate. Pre Diagnostics operates in a highly competitive space with established players and significant regulatory hurdles. However, the unmet clinical need and the shift toward early diagnosis create substantial opportunities. Success will depend on the company's ability to differentiate its technology, forge strategic partnerships, and navigate the regulatory pathway. If Pre Diagnostics can demonstrate robust clinical performance and secure financing, it could capture a meaningful share of the emerging neurodegenerative diagnostic market, estimated to reach billions of dollars in the coming decade.

Upcoming Catalysts (preview)

• 2026Series A Funding Round60% success
• 2027First Clinical Validation Study Initiation50% success
• 2026Strategic Partnership with Pharma or Diagnostic Company40% success